Professor Stephen (Steve) Wilton

Flynn LL, Mitrpant C, Pitout IL, Fletcher S, and Wilton SD, Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Mol Ther Nucleic Acids, 2018. (in press).

Flynn LL, Mitrpant C, Pitout IL, Fletcher S, and Wilton SD, Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Mol Ther Nucleic Acids, 2018. (in press).

Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, and Stick SM, The potential of antisense oligonucleotide therapies for inherited childhood lung diseases. Mol Cell Pediatr, 2018. 5(1): p. 3.

Corrigendum: Response to “Railroading at the FDA”. Letter to the editor. SD Wilton, S Fletcher and F Muntoni. Nature Biotechnology. (2017) DOI: 10.1038/nbt0517-481d

A Dominant-Negative COL6A1 Pseudoexon Insertion Is Skippable Using Splice-Modulating Oligonucleotides Bolduc V, Foley AR, Donkervoort S, Hu Y, Cummings BB, Lek M, Sarathy A, Sizov K, Degefa HS, Wagener R, Hennig GW, Hanssen E, Lamande SR, Muntoni F, Wilton SD, Macarthur DG, Bonnemann CG 2017 Molecular Therapy 25: 119-120

A common dominant-negative COL6A1 pseudo-exon insertion is skippable using splice-modulating oligonucleotides Bolduc V, Foley A, Donkervoort S, Hu Y, Cummings B, Lek M, Sarathy A, Sizov K, Degefa H, Wagener R, Hennig G, Hanssen E, Lamande S, Muntoni F, Wilton SD, Macarthur DG, Bonnemann C 2017 Neuromuscular Disorders 27: S177-S177

Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research Bellgard MI, Chartres N, Watts GF, Wilton SD, Fletcher S, Hunter A, Snelling T 2017 Front Public Health 5: 224

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro Le BT, Adams AM, Fletcher S, Wilton SD and Veedu RN 2017 Mol Ther Nucleic Acids 9: 155-161

Polyglutamine ataxias: From Clinical and Molecular Features to Current Therapeutic Strategies McIntosh CS, Aung-Htut MT, Fletcher S, Wilton SDJournal of Genetic Syndromes and Gene Therapies 8: 319. doi: 10.4172/2157-7412.1000319

Review: Inherited retinal disease therapy targeting precursor messenger ribonucleic acid. Di Huang, Sue Fletcher, Samuel McLenachan, David A Mackey, Norman Palmer, Steve D Wilton, Fred Chen. Vision doi:10.3390/vision1030022.